Higher blood aldosterone level in metabolic syndrome is independently related to adiposity and fasting plasma glucose

Cardiovascular Diabetology

Wei-Shiung Yang³  Kuo-Chin Huang²  Yu-Chiao Chi¹  Feng-Yu Tseng³  Chi-Ling Chen⁴  Jui-Kun Chiang¹ 

[1] Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, 7 Chun-Shan South Road, Taipei 100, Taiwan;Family Medicine, National Taiwan University Hospital, Taipei, Taiwan;Departments of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan;Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan

关键词: Glucose;    Adiposity;    Adiponectin;    Metabolic syndrome;    Aldosterone;   

Others  :  1118923
DOI  :  10.1186/s12933-015-0175-6

 received in 2014-10-12, accepted in 2015-01-03,  发布年份 2015

【 摘 要 】

Background

Hypoadiponectinemia is a well-known state associated with metabolic syndrome (MetS) and insulin resistance (IR). Recently aldosterone has been highly associated with high blood pressure, and may thus be a possible biomarker for MetS and IR. In this study, we investigate the association of aldosterone with MetS and IR, and compare it with that of adiponectin.

Methods

In this cross-sectional study, we recruited 556 women receiving physical examinations at a general hospital in central Taiwan. At the time of examination, we collected data on various demographic and physical characteristics and measured blood levels of aldosterone, adiponectin and a variety of metabolic factors. Multiple linear regression analysis was performed using adiponectin or aldosterone as the dependent variables.

Results

We found an inverse correlation between blood adiponectin and aldosterone (γ = −0.11, P = 0.009). Adiponectin levels were lower and aldosterone levels higher in women with MetS that those without (8.1 ± 0.4 vs. 11.5 ± 0.2 μg/mL, P < 0.001 and 691 ± 50 vs. 560 ± 11 pmol/L, P = 0.013, respectively), as they were in women with and without IR (adiponectin 10.4 ± 0.5 vs. 11.3 ± 0.2 μg/mL, P = 0.003 and aldosterone 635 ± 31 vs. 560 ± 11 pmol/L, P = 0.022). Although aldosterone was significantly related to body fat %, fasting plasma glucose and serum creatinine levels, the relationship between adiponectin and aldosterone was not obvious after adjustment in the multivariate analysis.

Conclusion

Although aldosterone was related to metabolic factors, including body fat % and fasting plasma glucose in our female subjects, the relationship between aldosterone and adiponectin remains unclear.

【 授权许可】

   
2015 Chiang et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, Chuang LM: Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001, 86(8):3815-9.
• [2]Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, Chuang LM: Plasma adiponectin levels in overweight and obese Asians. Obes Res 2002, 10(11):1104-10.
• [3]Huang KC, Chen CL, Chuang LM, Ho SR, Tai TY, Yang WS: Plasma adiponectin levels and blood pressures in nondiabetic adolescent females. J Clin Endocrinol Metab 2003, 88(9):4130-4.
• [4]Chang LC, Huang KC, Wu YW, Kao HL, Chen CL, Lai LP, Huang JJ, Yang WS: The clinical implications of blood adiponectin in cardiometabolic disorders. J Formos Med Assoc 2009, 108(5):353-66.
• [5]Lu JY, Huang KC, Chang LC, Huang YS, Chi YC, Su TC, Chen CL, Yang WS: Adiponectin: a biomarker of obesity-induced insulin resistance in adipose tissue and beyond. J Biomed Sci 2008, 15(5):565-76.
• [6]Fisman EZ, Tenenbaum A: Adiponectin: a manifold therapeutic target for metabolic syndrom, diabetes, and coronary disease? Cardiovasc Diabetol 2014, 13:103. BioMed Central Full Text
• [7]Bogaert YE, Linas S: The role of obesity in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2009, 5(2):101-11.
• [8]Ostergren J: Renin-angiotensin-system blockade in the prevention of diabetes. Diabetes Res Clin Pract 2007, 76(Suppl 1):S13-21.
• [9]Kurtz TW, Pravenec M: Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens 2004, 22(12):2253-61.
• [10]Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K: Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003, 42(1):76-81.
• [11]Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Kang MH, Ahn TH, Choi IS, Shin EK: Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004, 110(24):3687-92.
• [12]Yong QC, Thomas CM, Seqqat R, Chandel N, Baker KM, Kumar R: Angiotensin type 1a receptor-deficient mice develop diabetes-induced cardiac dysfunction, which is prevented by renin-andiotensin system inhibitors. Cardiovasc Diabetol 2013, 12:169. BioMed Central Full Text
• [13]Ramachandran V, Ismail P, Stanslas J, Shamsudin N: Analysis of renin-angiotensin aldosterone system gene polymorphisms in malaysian essential hypertensive and type 2 diabetic subjects. Cardiovasc Diabetol 2009, 8:11. BioMed Central Full Text
• [14]Urbanet R, Pilon C, Calcagno A, Peschechera A, Hubert EL, Giacchetti G, Gomez-Sanchez C, Mulatero P, Toffanin M, Sonino N, Zennaro MC, Giorgino F, Vettor R, Fallo F: Analysis of insulin sensitivity in adipose tissue of patients with primary aldosteronism. J Clin Endocrinol Metab 2010, 95(8):4037-42.
• [15]Widimský J Jr, Sindelka G, Haas T, Prázný M, Hilgertová J, Skrha J: Impaired insulin action in primary hyperaldosteronism. Physiol Res 2000, 49(2):241-4.
• [16]Fallo F, Della Mea P, Sonino N, Bertello C, Ermani M, Vettor R, Mulatero P: Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens 2007, 20(8):855-61.
• [17]Iacobellis G, Petramala L, Cotesta D, Pergolini M, Zinnamosca L, Cianci R, De Toma G, Sciomer S, Letizia C: Adipokines and cardiometabolic profile in primary hyperaldosteronism. J Clin Endocrinol Metab 2010, 95(5):2391-8.
• [18]Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, Rabbia F, Federspil G, Mulatero P: Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 2006, 91(2):454-9.
• [19]Sindelka G, Widimský J Jr, Haas T, Prázný M, Hilgertová J, Skrha J: Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment. Exp Clin Endocrinol Diabetes 2000, 108(1):21-5.
• [20]Briet M, Schiffrin EL: The role of aldosterone in the metabolic syndrome. Curr Hypertens Rep 2011, 13(2):163-72.
• [21]Hannemann A, Meisinger C, Bidlingmaier M, Döring A, Thorand B, Heier M, Belcredi P, Ladwig KH, Wallaschofski H, Friedrich N, Schipf S, Lüdemann J, Rettig R, Peters J, Völzke H, Seissler J, Beuschlein F, Nauck M, Reincke M: Association of plasma aldosterone with the metabolic syndrome in two German populations. Eur J Endocrinol 2011, 164(5):751-8.
• [22]Flynn C, Bakris GL: Interaction between adiponectin and aldosterone. Cardiorenal Med 2011, 1(2):96-101.
• [23]Newbern D, Gumus Balikcioglu P, Balikcioglu M, Bain J, Muehlbauer M, Stevens R, Ilkayeva O, Dolinsky D, Armstrong S, Irizarry K, Freemark M: Sex differeneces in biomarkers associated with insulin resistance in obese adolescents: metabolic profiling and principal components analysis. J Clin Endocrinol Metab 2014, 9:jc20142080. [Epub ahead of print]
• [24]Ferrario CM, Jessup JA, Smith RD: Hemodynamic and hormonal patterns of untreated essential hypertension in men and women. Ther Adv Cardiovasc Dis 2013, 7(6):293-305.
• [25]Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matzuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino T, Funahashi T, Matsuzawa Y: Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002, 51(9):2734-41.
• [26]Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412-9.
• [27]Hu E, Liang P, Spiegelman BM: AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996, 271(18):10697-703.
• [28]Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996, 221(2):286-9.
• [29]Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8(11):1288-95.
• [30]Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M: The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981, 304(16):930-3.
• [31]MacKenzie SM, Huda SS, Sattar N, Fraser R, Connell JM, Davies E: Depot-specific steroidogenic gene transcription in human adipose tissue. Clin Endocrinol (Oxf) 2008, 69(6):848-54.
• [32]Jonsson JR, Game PA, Head RJ, Frewin DB: The expression and localisation of the angiotensin-converting enzyme mRNA in human adipose tissue. Blood Press 1994, 3(1–2):72-5.
• [33]Karlsson C, Lindell K, Ottosson M, Sjostrom L, Carlsson B, Carlsson LM: Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab 1998, 83(11):3925-9.
• [34]Sowers JR, Whaley-Connell A, Epstein M: Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009, 150(11):776-83.
• [35]Mosso LM, Carvajal CA, Maiz A, Ortiz EH, Castillo CR, Artigas RA, Fardella CE: A possible association between primary aldosteronism and a lower beta-cell function. J Hypertens 2007, 25(10):2125-30.
• [36]Basoglu OK, Sarac F, Sarac S, Uluer H, Yilmaz C: Metabolic syndrome, insulin resistance, fibrinogen, homocysteine, leptin, and C-reactive protein in obese patients with obstructive sleep apnea syndrome. Ann Thorac Med 2011, 6(3):120-5.
• [37]Barceló A, Piérola J, Esquinas C, de la Peña M, Arqué M, Alonso-Fernández A, Bauçà JM, Robles J, Barceló B, Barbé F: Relationship between aldosterone and the metabolic syndrome in patients with obstructive sleep apnea hypopnea syndrome: effect of continuous positive airway pressure treatment. PLoS One 2014, 9(1):e84362.
• [38]Kamide K. Role of renin-angiotensin-aldosterone system in metabolic syndrome and obesity-related hypertension. Curr Hypertens Rev. 2014. [Epub ahead of print].
• [39]Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, Woerle HJ, von Eynatten M, Broedl UC: The effect of empaglifolzin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014, 13:28. BioMed Central Full Text
• [40]Ramírez E, Klett-Mingo M, Ares-Carrasco S, Picatoste B, Ferrarini A, Rupérez FJ, Caro-Vadillo A, Barbas C, Egido J, Tuñón J, Lorenzo Ó: Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes. Cardiovasc Diabetol 2013, 12:172. BioMed Central Full Text
• [41]Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, Hauner H, McCann SM, Scherbaum WA, Bornstein SR: Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A 2003, 100(24):14211-6.